Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
The trial tested whether semaglutide -- the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- helped slow progression for Alzheimer's disease. The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025.
Novo's Worst Year Is Your Best Opportunity
I argue that 2025 was the "peak pain" year for Novo Nordisk, and I believe the massive stock correction has gone "too far," creating a compelling GARP opportunity. I believe that despite a guidance cut and pricing pressure, the company's underlying business remains strong, with temporary restructuring costs masking its true profitability. I see major upcoming catalysts, including the launch of an oral version of Wegovy and the 2026 filing for its next-generation drug CagriSema, which I expect will reignite growth.
Novo Nordisk: The Sell-Off Is Getting Absolutely Ridiculous
Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering Novo's presence in two of the most promising healthcare segments. By underlying realistic growth rates, Novo is undervalued by up to 85%.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: One Of The Most Mispriced Alphas In The Market
Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market leadership. NVO dominates international markets with 72% share and 335% Wegovy sales growth, while Wall Street fixates on US market share losses. CagriSema and oral GLP-1 pipeline offer superior efficacy, broader access, and are key to unlocking massive untapped global demand.
Novo Nordisk: Will Wegovy And Pipeline Spark Rally?
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 billion in the 3rd quarter. Yes, Ozempic remains a "dark spot" in Novo Nordisk's GLP-1 franchise, but at the same time, its sales grew by 3.2% year on year.
Novo Nordisk: Potential Winner With Value Trap Risks
NVO's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock prices/performance, upon the materialization of positive catalyst/bullish support. This is significantly aided by the rich cash flow generation, the growing book value per share at $38.23, and the promising emergence of a double bottom indicator. Otherwise, there is no denying the numerous growth headwinds tied to NVO's investment thesis across the drug price deals, the therapy's mixed efficacy rates, and the GLP-1 price war.
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
For investors in Novo Nordisk NYSE: NVO, 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting competitive pressures and concerns about slowing growth in its key GLP-1 franchise.
Novo Nordisk: A Rare Second Chance
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered guidance, and intensifying competition, but double-digit growth and strong pipeline remain intact. Valuation is compelling: Novo Nordisk trades near its lowest P/E in 20 years and offers a solid free cash flow yield, with intrinsic value estimates well above current price.
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash-paying patients. The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of the drugs for $199 per month for the first two months of treatment.
